Resources

Proteomics Databases



Metabolomics Databases

• • Antibody Diversity And Specificity Analysis vs ELISA: Method Selection and Research Use Cases

  Technical guide for Antibody Diversity And Specificity Analysis vs ELISA: Method Selection and Research Use Cases.

• • Antibody Diversity And Specificity Analysis Troubleshooting: Causes, Checks, and Fixes for Research Workflows

  Technical guide for antibody diversity and specificity analysis troubleshooting with workflow checks, de novo sequencing decision logic, and interpretation limits.

• • How to Plan an Antibody Protein Sequencing Project When the Antibody Gene Sequence Is Unknown

  Antibody protein sequencing is often requested when a functional monoclonal antibody exists, but the antibody gene sequence is unknown, missing, or no longer trusted. A legacy hybridoma may still produce IgG, a recombinant batch may bind as expected, and internal records may list clone names or assay data, yet the exact VH and VL sequences needed for expression design, rescue, or documentation were never archived.

• • Epitope vs Antigen: Method Selection and Research Use Cases

  Decision-focused technical guide for selecting between antigen identification, epitope mapping, and staged de novo sequencing workflows in antibody-reactive samples.

• • How to Improve Antibody Diversity And Specificity Analysis Optimization in Research Workflows

  A decision-focused guide for immunology and antibody teams on resolving ambiguous diversity and specificity conclusions with protein-level sequence interpretation and validation planning.

• • Antigen vs Epitope: Method Selection and Research Use Cases

  Method-selection guide comparing antigen-level identification, epitope mapping, and de novo sequencing pathways for sequence-uncertain research projects.

• • How Much Does Hybridoma Sequencing Cost? Key Factors in Antibody Gene Recovery

  Researchers evaluating hybridoma sequencing often ask for a single price before hybridoma status, reporting scope, and deliverable needs are clear. That question is understandable. Grant budgets, vendor comparisons, and rescue timelines all depend on cost predictability. However, hybridoma sequencing is rarely a one-size-fits-all service.

• • Hybridoma Sequencing vs Antibody Protein Sequencing: Which Method Is More Suitable?

  Antibody sequence recovery projects often reach a fork in the road. A team may have a functional monoclonal antibody, but the available material may be hybridoma cells, RNA, purified IgG, or only a partial historical record. Hybridoma sequencing recovers VH and VL from hybridoma- derived nucleic acids. Antibody protein sequencing recovers sequence information from purified antibody protein, usually through LC-MS/MS and peptide assembly.

• • How to Perform Hybridoma Sequencing: Key Steps for Obtaining Antibody Variable Region Sequences

  Hybridoma sequencing is often requested when a monoclonal antibody is available from a hybridoma cell line, but the VH and VL sequences are missing from lab records. A culture may still produce antibody, binding assays may look acceptable, and frozen stocks may remain in storage, yet the variable-region sequences needed for recombinant expression, clone backup, or documentation were never archived.

• • Hybridoma Sequencing: Principles and Applications for Monoclonal Antibody Characterization

  Hybridoma sequencing addresses this gap by recovering antibody sequence information directly from hybridoma-derived nucleic acids. The method uses viable hybridoma cells or high-quality RNA as input, converts immunoglobulin transcripts to cDNA, amplifies variable regions by PCR, and assembles VH and VL sequences with CDR annotation.